GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 19 Dec 2016.
Inhibitor of Bruton agammaglobulinemia tyrosine kinase
IBtk, Btk-binding protein, inhibitor of Bruton's tyrosine kinase
The protein encoded by this gene binds to Bruton's tyrosine kinase (BTK) and downregulates BTK's kinase activity. In addition, the encoded protein disrupts BTK-mediated calcium mobilization and negatively regulates the activation of nuclear factor-kappa-B-driven transcription. [provided by RefSeq, Jul 2008] (from
Takahara et al., Tokyo, Japan. In Int J Hematol, Jan 2016
UNLABELLED: In this phase I dose-escalation study we evaluated the safety, tolerability, pharmacokinetics, and antitumor activity of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK, in Japanese patients with relapsed/refractory B cell malignancies (RRBCM).
HELIOS investigators et al., Jacksonville, United States. In Lancet Oncol, Jan 2016
We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Rule et al., Plymouth, United Kingdom. In Ther Clin Risk Manag, 2014
Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase, which functions by irreversible inhibition of the downstream signaling pathway of the B-cell receptor, which normally promotes cell survival and proliferation.